The association between previous use of anti‐obesity medication and semaglutide weight loss outcomes
Diabetes, Obesity and Metabolism · 2024-06 · 26 (6) · 2167-2175
DOI: 10.1111/dom.15523 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 12.03.2024. Verfasst von Wissam Ghusn und 11 weiteren Autor:innen. Beteiligte Einrichtung: Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Weight Loss, Glucagon-Like Peptides, Obesity, Anti-Obesity Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Aims
To compare weight loss outcomes between patients starting semaglutide who had previously been on another anti‐obesity medication (AOM) compared to those who were AOM‐naïve. Materials and Methods We performed a retrospective study in patients with overweight or obesity taking semaglutide for weight loss for a duration of 3 to 12 months. Our primary endpoint was assessment of percentage of total body weight loss (TBWL) in patients who started semaglutide as their first AOM (AOM‐naïve) compared to those who started semaglutide and had previously taken another AOM (non‐AOM‐naïve). The secondary outcome was a comparison of the proportions of patients achieving ≥5%, ≥10%, ≥15% and ≥20% TBWL between the groups. Our endpoints were analysed using independent t ‐tests and ANOVA/ANCOVA for continuous variables and Pearson's test for categorical variables.
Results
This study included 305 patients. Outcomes of semaglutide treatment were superior in AOM‐naïve patients ( n = 231) compared to non‐AOM‐naïve patients ( n = 74) at 3 (6.3% vs. 3.8%), 6 (10.6% vs. 6.7%), 9 (14.0% vs. 9.1%) and 12 months (14.3% vs. 10.6%; p < 0.0001 at 3, 6 and 9 months, and p = 0.01 at 12 months). A greater proportion of patients in the AOM‐naïve group achieved a TBWL ≥ 15% (48% vs 21%; p = 0.02) and ≥20% (27% vs 4% p < 0.01) at 12 months.
Conclusion
The use of semaglutide in patients with previous intake of other AOMs was associated with inferior weight loss outcomes in comparison to patients who were AOM‐naïve.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA.
ORCID-Profile: Wissam Ghusn, Sima Fansa, Diego Anazco
Förderung
- NIDDK NIH HHS
Zitieren
APA
Ghusn, W., Fansa, S., Anazco, D., Tama, E., Cifuentes, L., Gala, K., De La Rosa, A., Sacoto, D., Campos, A., Feris, F., Hurtado, D., & Acosta, A. (2024). The association between previous use of anti‐obesity medication and semaglutide weight loss outcomes. Diabetes, Obesity and Metabolism, 26(6), 2167-2175. https://doi.org/10.1111/dom.15523
Vancouver
Ghusn W, Fansa S, Anazco D, Tama E, Cifuentes L, Gala K, et al. The association between previous use of anti‐obesity medication and semaglutide weight loss outcomes. Diabetes, Obesity and Metabolism. 2024;26(6):2167-2175. doi:10.1111/dom.15523
BibTeX
@article{Ghusn2024,
author = {Ghusn, Wissam and Fansa, Sima and Anazco, Diego and Tama, Elif and Cifuentes, Lizeth and Gala, Khushboo and De La Rosa, Alan and Sacoto, Daniel and Campos, Alejandro and Feris, Fauzi and Hurtado, Daniela and Acosta, Andres},
title = {The association between previous use of anti‐obesity medication and semaglutide weight loss outcomes},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
volume = {26},
number = {6},
pages = {2167--2175},
doi = {10.1111/dom.15523}
}
EUVIMED